Please login to the form below

Not currently logged in
Email:
Password:

HTA guidance from NICE, the SMC and the AWMSG

Here we present a feed of upcoming health technology assessment (HTA) decisions, covering appraisals by the National Institute of Health and Care Excellence (NICE), the Scottish Medicines Consortium (SMC) and the All Wales Medicines Strategy Group (AWMSG).

Provided by Guidelines, it also features: NICE clinical guidelines, NICE quality standards, NICE evidence updates, NICE evidence summaries, independent professional body guidelines and (Scottish Intercollegiate Guidelines Network (SIGN) guidance.

Combined hormonal contraception—update (Faculty of Sexual & Reproductive Healthcare)

September 2018: Independent professional body guideline

Asthma (update)

September 2018: NICE Quality Standard

Depression in adults (update)

September 2018: NICE Quality Standard

Eating disorders

September 2018: NICE Quality Standard

Ovarian cancer (refresh)

September 2018: SIGN guidance

Renal replacement therapy

October 2018: NICE Clinical Guideline

Decision making and mental capacity

October 2018: NICE Social Care Guidance

Foetal alcohol spectrum disorder (update)

October 2018: SIGN guidance

Abdominal aortic aneurysm: diagnosis and management

November 2018: NICE Clinical Guideline

Contraceptive choices for women who are obese/overweight

November 2018: Independent professional body guideline

Visit the Guidelines website

Akcea steals march on Alnylam with NICE approval

Akcea steals march on Alnylam with NICE approval 16 Apr 2019
Advantage to Tegsedi over Onpattro. NICE has recommended Akcea Therapeutics’ rare disease treatment Tegsedi (inotersen), after the company improved its price offer. ... NICE’s ruling adds to the good news for Akcea, which in March gained a CHMP

NICE says no to Novartis’ Kisqali combo in breast cancer

NICE says no to Novartis’ Kisqali combo in breast cancer 11 Apr 2019
Double blow after Lilly rival recommended. Novartis’ hopes of a boost for under-performing breast cancer drug Kisqali have been hit by a negative verdict from NICE. ... by NICE alongside fulvestrant for this patient group last week, albeit via the

NICE nod for Lilly’s breast cancer drug Verzenio via CDF

NICE nod for Lilly’s breast cancer drug Verzenio via CDF 2 Apr 2019
In this case, NICE is waiting on the final analysis of the MONARCH 2 study is available, which is expected to be available in February 2020. ... NICE notes in its guidance that Verzenio and fulvestrant will be an option “where exemestane plus

NICE recommends MSD’s diabetes drug Steglatro

NICE recommends MSD’s diabetes drug Steglatro 28 Mar 2019
In the UK, the treatment is priced at £29.40 for 28 days, a price which NICE points out is the lowest acquisition cost of any SGLT-2 inhibitor. ... The decision by NICE shows MSD’s commitment to meeting the needs of a growing population of people with

NICE green light for Imfinzi in groundbreaking early lung cancer treatment

NICE green light for Imfinzi in groundbreaking early lung cancer treatment 28 Mar 2019
Early treatment opens up possibility of cure. AstraZeneca's immunotherapy Imfinzi has been recommended by NICE for patients with stage 3 non-small cell lung cancer (NSCLC). ... NICE has given the green light via the Cancer Drugs Fund (CDF), which means

More news from PMLiVE on NICE, the SMC and the AWMSG

MGP’s Guidelines brand is trusted by over 58,000 healthcare professionals for concise clinical summaries of major primary and shared care guidelines in the UK. Through Guidelines, Guidelines for Nurses and Guidelines in Practice, MGP connect pharmaceutical and medical device companies to an engaged audience of GPs, GP commissioners and payers, nurses and allied healthcare professionals.

To discuss how we can support your guidance or implementation needs please contact marketing@mgp.co.uk

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Apex.co.uk Conferences, Events and Exhibition Stands

Apex.co.uk is one of the UK’s leading event and exhibition agencies, specialising in healthcare. We understand your communication goals, whether...

Infographics